Susan Taylor, MD

Three subtle physical findings can signal that vitiligo is about to spread. Dr. Hamzavi outlines the warning signs of active disease and the practical scoring approach he uses instead of research metrics.

A careful physical exam, targeted laboratory testing, and a low threshold for biopsy remain the foundation of vitiligo diagnosis. Dr. Desai details the workup he uses with every new patient.

Vitiligo begins with oxidative stress and ends with CD8-positive T cells destroying melanocytes that cannot easily regenerate. Dr. Hamzavi maps the autoimmune cascade and the disease associations clinicians should watch for.

Vitiligo affects up to two percent of the population worldwide, yet payers and patients alike still misread it as cosmetic. Dr. Desai explains the autoimmune biology, systemic comorbidities, and diagnostic pitfalls that argue otherwise.

A deeper understanding of vitiligo's autoimmune mechanisms has fundamentally transformed vitiligo care, explains Susan Taylor, MD.